Navigation Links
Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
Date:2/5/2010

CRANBURY, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that its Board of Directors has elected John F. Crowley as Chairman of the Board in addition to his current role as Chief Executive Officer (CEO), effective immediately.  Mr. Crowley will succeed Donald J. Hayden, Jr., who will become the Lead Independent Director of the Board.

"The Board's decision to elect Mr. Crowley as Chairman of the Board reflects our confidence in his leadership and vision for Amicus.  Additionally, the Board recognized the value of the strong independent leadership provided by Mr. Hayden during his tenure as Chairman which will be preserved through his appointment as Lead Independent Director," stated Alexander Barkas, Ph.D., Amicus Board of Director and Member of Governance and Nominating Committee.

In his role as Chairman of the Board, Mr. Crowley will lead the Board's efforts in overseeing the development and implementation of the Company's strategic vision.  

As Lead Independent Director, Mr. Hayden will be responsible for, among other things, leading executive sessions of the Board's independent directors, advising the independent board committee chairs in fulfilling their responsibilities to the Board, assisting the Board and the Company's Officers in complying with Amicus' governance guidelines and overseeing the process of evaluating, developing and compensating the CEO.  A copy of the Lead Independent Director Charter describing in full Mr. Hayden's roles and responsibilities is available on the Amicus website at www.amicustherapeutics.com.

About Amicus Therapeutics

Amicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease.

FOLD –G

SOURCE Amicus Therapeutics

RELATED LINKS
http://www.amicustherapeutics.com

'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... 17, 2017 , ... DuPont Pioneer today announced the launch ... (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists is now available ... biologicals and digital solutions. , “DuPont Pioneer is building on its long history ...
(Date:7/16/2017)... ... July 16, 2017 , ... ... analytical instruments announced the launch of its new line of Extreme Environment Shakers ... applications that require CO2 and humidity for optimal cell growth such as cell ...
(Date:7/14/2017)... ... July 14, 2017 , ... Sonic Manufacturing ... Manufacturing Technologies has installed a solar system on its roof top. “We will ... President of Sonic, Kenneth Raab stated. The company’s proud history of social responsibility ...
(Date:7/14/2017)... ... July 13, 2017 , ... LGC ... kit has received US FDA 510 (k) clearance for use on Siemens Sysmex® ... D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A “equal delta” sample ...
Breaking Biology Technology:
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
Breaking Biology News(10 mins):